Skip to main navigation
Skip to search
Skip to main content
University of Birmingham Home
Help & FAQ
Link opens in a new tab
Search content at University of Birmingham
Home
Research output
Profiles
Research units
Projects
Activities
Datasets
Equipment
Prizes
Press/Media
Ustekinumab: a novel therapeutic option in Crohn's disease
E G Simon
, Subrata Ghosh
, G W Moran
Immunology and Immunotherapy
Research output
:
Contribution to journal
›
Article
›
peer-review
6
Citations (Scopus)
Overview
Fingerprint
Fingerprint
Dive into the research topics of 'Ustekinumab: a novel therapeutic option in Crohn's disease'. Together they form a unique fingerprint.
Sort by
Weight
Alphabetically
Keyphrases
Novel Therapeutics
100%
Crohn's Disease
100%
Ustekinumab
100%
Moderate to Severe
50%
Randomized Controlled Trial
25%
Tumor Necrosis Factor-α
25%
Interleukin-12 (IL-12)
25%
Monoclonal Antibody
25%
Remission Induction
25%
Interleukin-23 (IL-23)
25%
Anti-tumor Necrosis Factor Agents
25%
Crohn's
25%
Maintenance of Remission
25%
P40 Subunit
25%
Compassionate Use Program
25%
Pharmacology, Toxicology and Pharmaceutical Science
Crohn's Disease
100%
Ustekinumab
100%
Randomized Controlled Trial
25%
Remission
25%
Monoclonal Antibody
25%
Tumor Necrosis
25%
Tumor Necrosis Factor Inhibitor
25%